Tagrisso Osimertinib 80 Mg Tablets

Tagrisso Osimertinib 80 Mg Tablets is a prescription anticancer medicine containing osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI). It is specifically designed for patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations. By selectively targeting abnormal EGFR signaling pathways, Tagrisso helps inhibit cancer cell growth and supports better disease management.

Osimertinib tablets are commonly prescribed for patients with advanced or metastatic NSCLC with confirmed EGFR mutations. This targeted therapy works at the molecular level to block signals that promote tumor proliferation, providing an effective option for slowing disease progression. It is typically administered orally under strict medical supervision as part of a personalized oncology treatment plan.

Tagrisso 80 mg is a prescription-only product intended for use under the guidance of a qualified oncologist. Proper adherence to dosing, storage, and medical monitoring ensures optimal efficacy and patient safety. This oncology product has become a trusted therapy for EGFR-mutated NSCLC, offering patients a clinically validated option for managing advanced lung cancer.

Product Features

• Contains Osimertinib, a third-generation EGFR inhibitor
• Used for EGFR mutation-positive non-small cell lung cancer
• Effective against T790M and other EGFR mutations
• Oral targeted therapy with once-daily dosing
• Helps inhibit tumour growth and spread
• Prescription-only oncology medicine

How It Helps

• Blocks abnormal EGFR signalling to slow NSCLC growth
• Effective against T790M and other EGFR mutations
• Reduces tumour proliferation and risk of spread
• Prescription-only oncology product under medical supervision